Cornerstone
Diabetes Almost Made the Inextricably Linked List for 2026. It Did Not.
Key takeaway
Every prior Physician Fee Schedule since 2023 added a new scenario to the inextricably linked dental list. The CY 2026 rule is the first one that did not, and it is not because nobody asked. Seven submissions came in. The largest group asked for diabetes. CMS read them, said no proposals this year, and moved on. That is a different kind of fact than a denial, and a practice that treats it like a denial anyway is the one exposed.
Every Physician Fee Schedule since the pathway was created has added something. CY 2023 wrote the first four scenarios. CY 2024 added chemotherapy, CAR-T, and high-dose bone-modifying agents. CY 2025 added dialysis and ESRD. The CY 2026 final rule is the first one in the pathway’s history that added nothing, and the reason is worth reading carefully, because it is not silence. CMS received seven public submissions asking for exactly that kind of addition, read them, and said no proposals this year. The largest group of those submissions asked for diabetes.
What did the CY 2026 submissions actually ask for?
The submissions
CMS received seven public submissions proposing new clinical scenarios for the inextricably linked dental coverage pathway. Many of them recommended scenarios involving diabetes mellitus, specifically the connection between dental infection and diabetes-associated retinopathy and nephropathy. At least one additional submitter proposed scenarios tied to autoimmune disease and oral health.
Source: CY 2026 Medicare Physician Fee Schedule final rule (CMS-1832-F), dental services section, Medicare Parts A and B payment for dental servicesThis is the same mechanism that has produced every addition to 42 CFR 411.15(i)(3) so far. The rule is not static. Interested parties, medical societies, advocacy groups, individual clinicians, submit scenarios during the comment period, and CMS decides whether the clinical link is strong enough to write into the regulation. Dialysis got in this way in the CY 2025 cycle. Diabetes did not get in this cycle, but it went through the same door.
What did CMS do with the submissions?
The disposition
CMS stated it is not making any proposals in response to the received submissions for CY 2026, and will take the information and recommendations into consideration for future rulemaking.
Source: CY 2026 Medicare Physician Fee Schedule final rule (CMS-1832-F)Read that sentence on its own terms. It is not “denied.” It is not “under review with a target date.” It is deferral without a deadline, which is a specific and slightly unusual middle state for a practice to plan around. The submissions are not dead. They are also not law. Both are true at once, and a billing decision made today has to sit on the second fact, not the hope built into the first.
Why does this distinction matter more than it looks like it should?
Because advocacy coverage of a rulemaking cycle and the rule itself are two different documents, and they travel through a dental office at different speeds. A hygienist or office manager who reads a trade summary of “CMS considering diabetes for dental coverage” six months from now, without reading the actual disposition, has a real chance of assuming the addition already happened, or is imminent enough to act on. The submissions were serious, clinically grounded, and covered a population far larger than dialysis or transplant patients. That seriousness is exactly what makes the deferral easy to mistake for progress toward coverage that has not been granted yet.
The inextricably linked pathway only reaches what 42 CFR 411.15(i)(3) enumerates. Nothing about a strong public-comment case changes that until CMS actually writes the scenario into the subparagraphs, the way it did for dialysis in 2025.
What the pathway currently covers, and what it does not
| Subparagraph | Scenario | Status for CY 2026 |
|---|---|---|
| (A) | Organ/stem cell transplant, cardiac valve procedures | In effect since CY 2023 |
| (B) | Jaw reconstruction after tumor removal | In effect since CY 2023 |
| (D) | Extractions before head/neck radiation | In effect since CY 2023 |
| (E) | Complications after cancer treatment, including osteoradionecrosis | In effect since CY 2023 |
| (F) | Dialysis and ESRD comprehensive workup | In effect since CY 2025 |
| Diabetes mellitus (retinopathy/nephropathy link) | Proposed by multiple CY 2026 submissions | Not adopted; deferred to future rulemaking |
| Autoimmune disease and oral health | Proposed by at least one CY 2026 submission | Not adopted; deferred to future rulemaking |
The left column is regulation. The bottom two rows are advocacy, current as of this rulemaking cycle, and nothing more than that until a future final rule says otherwise.
What should a practice actually do with this today?
Nothing changes in how a diabetic patient’s routine dental work gets billed. It bills dental, the way it did before this rulemaking cycle opened and closed. The action item here is not a new workflow to build. It is a specific misreading to guard against: do not let a claim, an internal policy memo, or a front-desk assumption treat the diabetes submissions as if they were adopted. The gap between “seven serious submissions were made” and “the regulation now covers this” is the exact gap a MAC will find if a claim tests it before the rule catches up.
The more useful habit this cycle reinforces is checking every Physician Fee Schedule release against the actual subparagraph list, not against the advocacy summary of what was proposed. That habit is what caught the dialysis addition in 2025 while it was still new. It is the same habit that keeps a practice from acting on a scenario that, this year, did not make it into the rule at all.
Where this comes from
The seven-submission count, the diabetes and autoimmune disease scenario descriptions, and CMS’s deferral language are drawn from the CY 2026 Medicare Physician Fee Schedule final rule (CMS-1832-F), dental services section, published in the Federal Register on November 5, 2025, effective for services furnished on or after January 1, 2026. The existing subparagraph structure and effective dates are the same source base used across this site’s other pieces on 42 CFR 411.15(i)(3), cross-checked against Cornell Law School’s Legal Information Institute rendering of the current codified text.
If your practice wants to confirm none of your diabetes-linked claims drifted onto the inextricably linked pathway on a misreading of this cycle, ClaimRail runs a free audit against your Open Dental data and flags exactly which claims are exposed.
Questions
Did the CY 2026 Medicare Physician Fee Schedule add diabetes to the inextricably linked dental coverage list?
No. CMS received seven public submissions requesting new clinical scenarios be added to 42 CFR 411.15(i)(3) for CY 2026. Several of them proposed diabetes mellitus, citing the connection between dental infection and diabetes-associated retinopathy and nephropathy. CMS did not finalize any of the seven, stating it would take the information into consideration for future rulemaking rather than acting on it for 2026.
What did the other submissions propose, besides diabetes?
At least one submitter proposed adding scenarios tied to autoimmune disease and oral health. CMS grouped this with the diabetes submissions and the rest of the seven total requests, and finalized none of them, using the same future-rulemaking language across the group.
Does this mean a dental claim tied to a patient's diabetes is billable under the inextricably linked pathway?
No. The pathway only covers the scenarios named in 42 CFR 411.15(i)(3)(A) through (F): organ and stem cell transplant, cardiac valve procedures, cancer treatment requiring radiation or chemotherapy or CAR-T or high-dose bone-modifying agents, jaw reconstruction after tumor removal, jaw fracture stabilization, and dialysis or ESRD. Diabetes and autoimmune disease are not on that list. A claim filed under the linked pathway citing a diabetes diagnosis alone, with no qualifying scenario, is filed on a basis the regulation does not currently support.
Is this the same as CMS permanently rejecting diabetes-linked dental coverage?
No, and that distinction matters for how a practice should read the rule going forward. 'Not making any proposals in response to the received submissions' is deferral, not denial. CMS kept the submissions on file for future rulemaking cycles rather than closing the question. The correct operating assumption for a practice today is that diabetes is not covered now, while the door for a future year remains open.
Where does the CY 2026 Physician Fee Schedule final rule address this?
In the dental services section, under Medicare Parts A and B payment for dental services, in the CY 2026 Medicare Physician Fee Schedule final rule (CMS-1832-F), published in the Federal Register on November 5, 2025 and effective for services on or after January 1, 2026.
Should a practice change anything about how it bills diabetic patients' dental work right now?
Only in the sense of confirming nothing has changed. A practice that was correctly billing diabetic patients' routine dental care as dental, not medical, before the CY 2026 rule should keep doing exactly that. The risk here runs the other direction: a claim submitted on the assumption that CMS was about to add diabetes, or on a misreading of advocacy coverage of the submissions as if it were a final rule, is a claim built on a scenario that does not exist in the regulation yet.
The next step
If a number in here matched your practice, that leak is measurable. The 12-Month Missing Money Scan reads your last twelve months of claims and finds the money already earned but never collected. 25% of what is recovered, 20% if you prepay. No recovery, no fee.
Get your 12-Month Missing Money Scan